$OTLC
Oncotelic Therapeutics, Inc.

2016 Q3 Form 10-Q Financial Statement

#000119312516668383 Filed on August 02, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.190M $1.300M $1.350M
YoY Change 4.39% -3.7% -22.86%
% of Gross Profit
Research & Development $2.075M $2.374M $1.981M
YoY Change -15.55% 19.84% -8.75%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $3.262M $3.670M $3.328M
YoY Change -9.36% 10.28% -15.19%
Operating Profit -$3.262M -$3.670M -$3.328M
YoY Change -9.36% 10.28% -15.19%
Interest Expense $30.00K $30.00K $10.00K
YoY Change 200.0% 200.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 -$1.000K
YoY Change -100.0% -83.33%
Pretax Income -$3.240M -$3.640M -$3.320M
YoY Change -9.75% 9.64% -15.52%
Income Tax
% Of Pretax Income
Net Earnings -$3.236M -$3.641M -$3.324M
YoY Change -9.91% 9.54% -15.4%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.12 -$0.14 -$0.13
COMMON SHARES
Basic Shares Outstanding 26.54M shares 26.54M shares 26.54M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.28M $19.34M $33.09M
YoY Change -46.18% -41.55% -8.77%
Cash & Equivalents $5.167M $7.939M $33.09M
Short-Term Investments $11.11M $11.40M
Other Short-Term Assets $930.0K $1.040M $470.0K
YoY Change 121.43% 121.28% 2511.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.21M $20.38M $33.56M
YoY Change -43.87% -39.29% -8.64%
LONG-TERM ASSETS
Property, Plant & Equipment $14.00K $19.00K $42.00K
YoY Change -61.11% -54.76% 50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $33.00K $33.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $47.00K $52.00K $75.00K
YoY Change -31.88% -30.67% -30.56%
TOTAL ASSETS
Total Short-Term Assets $17.21M $20.38M $33.56M
Total Long-Term Assets $47.00K $52.00K $75.00K
Total Assets $17.26M $20.43M $33.64M
YoY Change -43.84% -39.27% -8.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $532.0K $501.0K $178.0K
YoY Change 67.82% 181.46% -79.03%
Accrued Expenses $950.0K $1.120M $990.0K
YoY Change -31.16% 13.13% -10.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.485M $1.617M $1.166M
YoY Change -12.54% 38.68% -40.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.485M $1.617M $1.166M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.490M $1.620M $1.170M
YoY Change -12.35% 38.46% -40.0%
SHAREHOLDERS EQUITY
Retained Earnings -$275.0M -$271.8M -$257.3M
YoY Change 5.43% 5.65% 4.97%
Common Stock $290.8M $290.6M $289.7M
YoY Change 0.31% 0.3% 3.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.78M $18.81M $32.47M
YoY Change
Total Liabilities & Shareholders Equity $17.26M $20.43M $33.64M
YoY Change -43.84% -39.27% -8.71%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$3.236M -$3.641M -$3.324M
YoY Change -9.91% 9.54% -15.4%
Depreciation, Depletion And Amortization $10.00K $0.00 $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$3.070M -$3.540M -$2.620M
YoY Change 8.1% 35.11% -20.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $20.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $290.0K $1.210M
YoY Change
Cash From Investing Activities $290.0K $1.210M -$20.00K
YoY Change 2800.0% -6150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -10.00K
YoY Change -100.0% -100.07%
NET CHANGE
Cash From Operating Activities -3.070M -3.540M -2.620M
Cash From Investing Activities 290.0K 1.210M -20.00K
Cash From Financing Activities 0.000 0.000 -10.00K
Net Change In Cash -2.780M -2.330M -2.650M
YoY Change -1.77% -12.08% -122.98%
FREE CASH FLOW
Cash From Operating Activities -$3.070M -$3.540M -$2.620M
Capital Expenditures $0.00 $20.00K
Free Cash Flow -$3.540M -$2.640M
YoY Change 34.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26544934 shares
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33093000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2016Q2 us-gaap Assets
Assets
20428000
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q2 us-gaap Assets Current
AssetsCurrent
20376000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290321000
CY2016Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
19341000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7939000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
265000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
501000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9842000 shares
CY2016Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
474000
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
19341000
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20428000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1617000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
406000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19000
CY2016Q2 us-gaap Short Term Investments
ShortTermInvestments
11402000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
18811000
CY2016Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1400000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.53
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271775000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
587000 shares
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1035000
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.30
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3275000 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2973000 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.41
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4139000 shares
CY2016Q2 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
864000 shares
CY2016Q2 oxgn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
236000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30031000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2015Q4 us-gaap Assets
Assets
27453000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
27390000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
289894000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27285000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
265000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287000
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9842000 shares
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
636000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27453000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2103000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
262000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
25350000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264809000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2695000 shares
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
105000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2031000 shares
CY2015Q4 oxgn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
918000
CY2016Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3062000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2455000
us-gaap Depreciation
Depreciation
10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Operating Expenses
OperatingExpenses
6105000
us-gaap Net Income Loss
NetIncomeLoss
-6096000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
149000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6105000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9195000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-253000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6118000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9195000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3650000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
us-gaap Share Based Compensation
ShareBasedCompensation
370000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23835000 shares
dei Entity Registrant Name
EntityRegistrantName
MATEON THERAPEUTICS INC
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000908259
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19346000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2668000
us-gaap Depreciation
Depreciation
11000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Operating Expenses
OperatingExpenses
7022000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
4202000
us-gaap Net Income Loss
NetIncomeLoss
-6966000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11402000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
930000
oxgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
2223000 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
-7022000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
15604000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-486000
us-gaap Investment Income Interest
InvestmentIncomeInterest
57000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7944000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.72
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.27
dei Trading Symbol
TradingSymbol
OXGN
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4354000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
115000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
427000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2223000 shares
oxgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited
115000 shares
oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y6M18D
oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P6Y9M15D
oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
2.40
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1347000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3328000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3324000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3328000
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1981000
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1296000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
3670000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-3641000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3670000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2374000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares

Files In Submission

Name View Source Status
0001193125-16-668383-index-headers.html Edgar Link pending
0001193125-16-668383-index.html Edgar Link pending
0001193125-16-668383.txt Edgar Link pending
0001193125-16-668383-xbrl.zip Edgar Link pending
d208387d10q.htm Edgar Link pending
d208387dex311.htm Edgar Link pending
d208387dex312.htm Edgar Link pending
d208387dex321.htm Edgar Link pending
d208387dex41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g208387ex41pg001.jpg Edgar Link pending
oxgn-20160630.xml Edgar Link completed
oxgn-20160630.xsd Edgar Link pending
oxgn-20160630_cal.xml Edgar Link unprocessable
oxgn-20160630_def.xml Edgar Link unprocessable
oxgn-20160630_lab.xml Edgar Link unprocessable
oxgn-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending